{"id":"NCT00818324","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Long Term Administration Study of OPC-12759 Ophthalmic Suspension","officialTitle":"Long Term Administration Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2010-09","completion":"2011-01","firstPosted":"2009-01-07","resultsPosted":"2014-02-26","lastUpdate":"2014-02-26"},"enrollment":154,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndromes"],"interventions":[{"type":"DRUG","name":"OPC-12759 Ophthalmic suspension","otherNames":[]}],"arms":[{"label":"OPC-12759 Ophthalmic suspension","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate safety and efficacy of OPC-12759 ophthalmic suspension during 52 weeks in dry eye patients","primaryOutcome":{"measure":"Change From Baseline (CFB) in Fluorescein Corneal Staining (FCS) Score","timeFrame":"Baseline, Week2, Week4, Week28, Week52","effectByArm":[{"arm":"2% Rebamipide Group","deltaMin":-2.2,"sd":2.3}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":154},"commonTop":["Nasopharyngitis","Dysgeusia (bitter taste)","Conjunctival haemorrhage","Conjunctivitis allergic","Trichiasis"]}}